SCHEMBL31228666

SCHEMBL31228666

O=C1SC(=Cc2ccc(F)cc2)C(=O)N1CCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.61
▸ ENPP2 Q13822 1/20 0.53
▸ MAOA P21397 2/20 0.52
▸ MAOB P27338 2/20 0.52
▸ FFAR1 O14842 1/20 0.52
▸ AMY1A P0DUB6 1/20 0.49
▸ PTPN1 P18031 1/20 0.49
▸ DPP4 P27487 1/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ AKR1B1 P15121 1/20 0.48
▸ CISD1 Q9NZ45 2/20 0.48
▸ MAPK1 P28482 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2548401 0.76 PIM1 (1.00) PIM1ENPP2AKR1B1SMN1; SMN2MEN1
SCHEMBL2548399 0.76 PIM1 (1.00) PIM1ENPP2AKR1B1SMN1; SMN2MEN1
SCHEMBL14560445 0.75 MAOA (0.65) MAOAMAOBNPC1LMNARAB9A
SCHEMBL4207901 0.74 AKR1B1 (0.59) PIM1ENPP2MAOAMAOBPTPN1
SCHEMBL4207906 0.74 AKR1B1 (0.59) PIM1ENPP2MAOAMAOBPTPN1
SCHEMBL20534356 0.74 AKR1B1 (0.78) PTPN1AKR1B1MAPT
SCHEMBL20534357 0.74 AKR1B1 (0.78) PTPN1AKR1B1MAPT
SCHEMBL6691625 0.73 PPARG (0.69) PIM1ENPP2PTPN1LMNAL3MBTL1
SCHEMBL6691628 0.73 PPARG (0.69) PIM1ENPP2PTPN1LMNAL3MBTL1
SCHEMBL13446896 0.73 MMP1 (0.73) MAOAMAOBFFAR1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12150935-B1 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2024-11-26 — — US disclosed
US-12150935-B1 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2024-11-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12150935-B1 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer MCL1, CASP3, ACIN1 PIM1 1227/4885ENPP2 3293/4885MAOA 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback